Table 1. Descriptive statistics of the study population
| ACVIM MMVD stage | Number of patients (%) | MMVD stage progression | Number of patients by stage progression (%) | Average time to stage progression (S.D.)1) |
| B1 | 166 (45.36) | Not progressed | 146 (87.95) | |
| Progressed | 20 (12.05) | 530.19 days (569.76) |
| B2 | 200 (54.64) | Not progressed | 183 (91.50) | |
| Progressed | 17 (8.50) | 407.37 days (268.07) |
Average time to stage progression is considered to be the closest of the dates that stage progression was diagnosed to the date of the initial diagnosis.
ACVIM, American College of Veterinary Internal Medicine; MMVD, myxomatous mitral valve disease.